News
01-11-2010, 11:23 PM
YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.
More... (http://www.news-medical.net/news/20100112/YM-BioSciences-announces-results-of-cancer-antibody-radionuclide-conjugate-development-collaboration.aspx)
More... (http://www.news-medical.net/news/20100112/YM-BioSciences-announces-results-of-cancer-antibody-radionuclide-conjugate-development-collaboration.aspx)